Clinical Trials Logo

Suicidal Behavior clinical trials

View clinical trials related to Suicidal Behavior.

Filter by:

NCT ID: NCT03080168 Completed - Suicidal Ideation Clinical Trials

The "AIM Study": Investigating Whether Actigraphy and Ideation Measures Can Promote Patient Safety

AIM
Start date: February 21, 2017
Phase:
Study type: Observational

This is a research project looking at whether measuring movements or responses to certain questions can help predict suicidal thoughts or actions. This project has two parts: The first part will occur while the participant is receiving hospitalized at the Bedford VA Hospital. It involves wearing a watch-like device on his/her wrist and answering questions or doing tasks to measure mood and other mental health symptoms, and suicidal thoughts. In the second phase, the investigators will call the participant around 12 months after s/he has left the hospital. The investigators will discuss how s/he is doing and if s/he has had suicidal thoughts or made suicidal acts.

NCT ID: NCT02960191 Terminated - Suicidal Behavior Clinical Trials

Functional Neuroimaging and Genetic Vulnerability to Suicidal Behavior

Start date: December 2008
Phase: N/A
Study type: Interventional

The main objective is to highlight, by functional imaging (MRI) dysfunctional brain regions associated with vulnerability to suicidal behavior.

NCT ID: NCT02904005 Recruiting - Depression Clinical Trials

Predictors of Suicidal Behavior in Depression

SECS
Start date: March 2015
Phase: N/A
Study type: Interventional

This study aims at identifying predictors of suicidal behaviors in depressed subjects. Investigators will first compare demographic, clinical, and biological features of depressed recent suicide attempters (within one week) and depressed subjects without lifetime history of suicide attempt. Baseline risk factors for suicide will be used to predict the risk of attempting suicide during a one year follow-up. A thorough evaluation of these patients will allow to identify the factors associated with suicidal risk and develop a simplified risk score that could be used in clinical settings to improve our practice.

NCT ID: NCT02824081 Recruiting - Clinical trials for Major Depressive Episode

Neuroinflammation, Serotonin, Impulsivity and Suicide

NISIS
Start date: November 2015
Phase: N/A
Study type: Interventional

Suicide is a major health problem that causes annually a million death worlwide. In the stress-vulnerability model, suicidal behavior (SB) results from the interaction between an individual's predisposition (personality, family history of SB…) and stressful conditions (early life adversity). Studies show that suicide ideations could favour inflammation and that depression is associated with an elevated inflammation. Recent evidences also suggest that inflammatory mediators play a critical role in SB. The aim of the study is to evaluate the inflammatory markers rate on depressed patients with or without personal history of SB. In the second part of the study, the relations between the rates of inflammatory markers and characteristics of SB, impulsivity, psychological pain, childhood abuse and gene expression of 5HT2B receptor will be investigated.

NCT ID: NCT01118195 Completed - Clinical trials for Traumatic Brain Injury (TBI)

Executive Dysfunction & Suicide: An Exploration Of Risk Factors In Traumatically Brain Injured Veterans

Start date: January 2007
Phase: N/A
Study type: Observational

This is a study to learn more about traumatic brain injury (TBI) and suicidal behaviors. The purpose of this research is to find out more about the issues related to these conditions. This study seeks to explore the relationship between executive dysfunction and suicidal behavior in an outpatient population.

NCT ID: NCT00449007 Terminated - Depression Clinical Trials

Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism

Start date: February 2006
Phase: Phase 4
Study type: Interventional

We will study patients with a current major depressive episode, comorbid alcoholism and a history of a past suicide attempt. All subjects with alcohol dependence will be evaluated for risk of alcohol withdrawal prior to randomization. The study will provide six months of antidepressant pharmacotherapy as well as psychotherapy focused on alcohol relapse prevention. Patients will also be encouraged to attend daily Alcoholics Anonymous meetings. The outcome measures will be: 1) occurrence of suicide events; 2) reduction of suicidal ideation; 3) reduction in neuropsychological measures of impulsivity.